Literature DB >> 12930393

Effective graft-versus-leukaemia effect after allogeneic stem cell transplantation using reduced-intensity preparative regimens in Fanconi anaemia patients with myelodysplastic syndrome or acute myeloid leukaemia.

Philippe Guardiola1, Peter Kurre, Amalia Vlad, Jean-Michel Cayuela, Hélène Espérou, Agnès Devergie, Patricia Ribaud, Gérard Socié, Patrice Richard, Richard Traineau, Rainer Storb, Eliane Gluckman.   

Abstract

Allogeneic transplantation is the only curative treatment for Fanconi anaemia (FA) patients who develop myeloid malignancies. Dose-intensive preparative regimens, to decrease disease recurrence, lead to unacceptable transplant-related toxicity in FA. We report the outcome of three FA patients with such malignancies who underwent transplantation with reduced-intensity preparative regimens. This approach was well tolerated, even as second transplantations, and resulted in complete leukaemic remissions. However, the graft-versus-leukaemia effect was associated with fatal graft-versus-host disease. Even after transplantation, myeloid malignancies remain associated with a poor outcome in FA, and this argues in favour of early intervention when suitable donors are available.

Entities:  

Mesh:

Year:  2003        PMID: 12930393     DOI: 10.1046/j.1365-2141.2003.04503.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.

Authors:  Richard Mitchell; John E Wagner; Betsy Hirsch; Todd E DeFor; Heather Zierhut; Margaret L MacMillan
Journal:  Br J Haematol       Date:  2013-10-30       Impact factor: 6.998

2.  Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia.

Authors:  Alexis Talbot; Régis Peffault de Latour; Emmanuel Raffoux; Nimrod Buchbinder; Stéphane Vigouroux; Noel Milpied; Thierry Leblanc; Jean Soulier; Mauricette Michallet; Gérard Socié
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.